Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00179023 · ClinicalTrials.gov registry record · Phase 1
The Autonomic Nervous System and Obesity
A Phase 1 study, sponsored by Vanderbilt University.
- Completed
- Registry status
- Phase 1
- Development phase
- 128
- Enrollment target
NCT00179023 is a Phase 1 study that has completed, run by Vanderbilt University. The registered enrollment target is 128 participants.
The verdict
NCT00179023, a Phase 1 study, has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 128 participants
- Enrollment target
Study Summary
In its simplest terms, obesity is the results of a positive balance between food intake and energy expenditure (EE). I.e., we take in more energy, in the form of food, than we expend, e.g., by exercise. In our sedentary society, resting EE accounts for most of total energy expenditure. The sympathetic nervous system (SNS, the one that produces adrenaline) is thought to contribute to resting EE. This conclusion is based on experiments where resting EE is decreased by beta-blockers, high blood pressure medicines that block only one aspect of the sympathetic nervous system. The investigators propose to use a different approach, by using a medication called trimethaphan that produces transient withdrawal of the autonomic nervous system. The investigators will then compare the measured resting EE before and after SNS withdraw and quantify the degree of contribution to the resting EE by the SNS and delineate differences between healthy normal, healthy obese, and patients with autonomic dysfunctions.
Interventions
- DRUG Trimethaphan
- DRUG Pseudoephedrine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2003-04 |
| Est. Completion | 2017-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00179023
The ClinicalTrials.gov registry entry for NCT00179023 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 128 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Trimethaphan is the first listed.
NCT00179023 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00179023 about?
NCT00179023 is a clinical study titled "The Autonomic Nervous System and Obesity". In its simplest terms, obesity is the results of a positive balance between food intake and energy expenditure (EE). I.e., we take in more energy, in the form of food, than we expend, e.g., by exercise. In our sedentary society, resting EE accounts for most of total energy expenditure. The sympathet...
What is the current status of trial NCT00179023?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 128 participants. The study started on 2003-04. Estimated completion is 2017-01.
What interventions are being tested in trial NCT00179023?
The interventions under investigation include: Trimethaphan (DRUG), Pseudoephedrine (DRUG).
Who is sponsoring clinical trial NCT00179023?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.